We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Glenmark’s current portfolio consists of 164 products authorised for distribution in the US marketplace and 46 ANDA’s pending approval with the US FDA.
Forward Pharma has lost its appeal on a US Patent Trial and Appeal Board decision that validated patents for Biogen's blockbuster MS drug Tecfidera (dimethyl fumarate).